Home › Biogen buys UK-based neuropathic pain drug developer for up to $675M
 

Keywords :   


Biogen buys UK-based neuropathic pain drug developer for up to $675M

2015-01-12 06:43:14| Biotech - Topix.net

Biogen Idec is getting into the neuropathic pain treatment field with the acquisition of a U.K. drug developer for up to $675 million. The Cambridge biotech firm , known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals on the first weekend of the J.P. Morgan Healthcare conference in San Francisco.

Tags: drug pain developer buys

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 5
More »